Hyperbranched Polymer-Based Vaccines for Cancer Immunotherapy

Macromol Biosci. 2023 Nov;23(11):e2300188. doi: 10.1002/mabi.202300188. Epub 2023 Jun 17.

Abstract

Recently, several immunotherapeutic strategies are extensively studied and entered clinical investigation, suggesting their potential to lead a new generation of cancer therapy. Particularly, a cancer vaccine that combines tumor-associated antigens and immune adjuvants with a nanocarrier holds huge promise for inducing specific antitumor immune responses. Hyperbranched polymers, such as dendrimers and branched polyethylenimine (PEI) possessing abundant positively charged amine groups and inherent proton sponge effect are ideal carriers of antigens. Much effort is devoted to design dendrimer/branched PEI-based cancer vaccines. Herein, the recent advances in the design of dendrimer/branched PEI-based cancer vaccines for immunotherapy are reviewed. The future perspectives with regard to the development of dendrimer/branched PEI-based cancer vaccines are also briefly discussed.

Keywords: antigen delivery; cancer vaccines; hyperbranched polymers; immunotherapy.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cancer Vaccines* / therapeutic use
  • Dendrimers* / pharmacology
  • Dendrimers* / therapeutic use
  • Humans
  • Immunotherapy
  • Neoplasms* / therapy
  • Polyethyleneimine
  • Polymers

Substances

  • Cancer Vaccines
  • Dendrimers
  • Polyethyleneimine
  • Polymers